SynthesisFrontiers in medicine2026
Efficacy and safety of GLP-1 receptor agonists in patients with metabolic-associated fatty liver diseases: an umbrella review.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) play a regulatory roles in metabolism across several tissues and have potential value in the treatment of MASLD. A novel umbrella review was conducted to assess the efficacy and safety of GLP-1 RAs in MASLD in multiple dimensions. Following the PRISMA 2020 guidance, five databases were searched from inception to 30 September, 2025. The quality of the included systematic reviews was assessed using AMSTAR 2. Twenty-three meta-analyses and systematic reviews were included. All outcomes regarding the efficacy of GLP-1 RAs in MASLD were summarized into five categories: liver characteristics, liver enzyme levels, anthropometric measurements, metabolic markers, and inflammatory markers. GLP-1 RAs show potential benefits in improving MASLD across multiple dimensions with a relatively acceptable safety profile, but nearly 80% of included reviews are of critically low quality with high evidence overlap. Thus, our findings are preliminary and hypothesis-generating. High-quality studies are urgently needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.